Roche in $548m macrocycle antibiotic deal
This article was originally published in Scrip
Executive Summary
Roche has signed an antibiotic development agreement worth up to CHF500m ($548m) in up-front and milestone payments for its partner, Polyphor, another Swiss company. The deal covers the development and commercialization of privately owned Polyphor's Phase II macrocycle antibiotic, POL7080, which has potential to treat serious, drug-resistant hospital infections.